Early access to TB006 for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This program provides access to an investigational drug called TB006 for people with Alzheimer's disease or related dementias who have run out of standard treatment options. It aims to see if the drug is safe and helpful in a real-world setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 55 years of age.
- You have been diagnosed with Alzheimer's disease or a related dementia, with a recent memory test score of 24 or less.
- Standard Alzheimer's medications either aren't an option for you, or you've kept getting worse despite taking them.
- You're not able to join another clinical trial (for example, there isn't one nearby or none you qualify for).
- You have a family member or friend who can come with you to clinic visits and help describe any changes you may have.
- You can travel to the clinic once a month for check-ins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called TML-6 for people with early Alzheimer's disease or mild cognitive impairment. It aims to see if the drug is safe and can help slow down memory and thinking problems.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This trial provides continued access to an investigational drug (TRx0237) for people with early or mild-moderate Alzheimer's disease. It aims to see if long-term use is safe and beneficial.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.